Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session: Sarcoma

1493MO - Peripheral immune biomarkers of survival in patients with resectable dedifferentiated liposarcomas (DDLPS) and undifferentiated pleomorphic sarcomas (UPS) treated with neoadjuvant nivolumab +/- ipilimumab (neoICB)


12 Sep 2022


Mini Oral session: Sarcoma


Immunotherapy;  Surgical Oncology

Tumour Site



Elise Nassif


Annals of Oncology (2022) 33 (suppl_7): S681-S700. 10.1016/annonc/annonc1073


E.F. Nassif1, E.Z. Keung1, P. Jiang2, A. Reuben2, S. Crosby3, G. Mathew3, A. Lazar4, K. Torres1, W. Wang5, A. Guadagnolo6, A. Bishop6, K.K. Hunt1, J. Bird7, V. Lewis7, A.P. Conley8, J.A. Wargo1, N. Somaiah9, C.L. Roland1

Author affiliations

  • 1 Surgical Oncology, MD Anderson Cancer Center, 77030 - Houston/US
  • 2 Thoracic H&n Med Onc, MD Anderson Cancer Center, 77030 - Houston/US
  • 3 Translational Molecular Path, MD Anderson Cancer Center, 77030 - Houston/US
  • 4 Pathology, The University of Texas M. D. Anderson Cancer Center, 77030 - Houston/US
  • 5 Pathology, MD Anderson Cancer Center, 77030 - Houston/US
  • 6 Radiation Oncology, MD Anderson Cancer Center, 77030 - Houston/US
  • 7 Orthopaedic Oncology, MD Anderson Cancer Center, 77030 - Houston/US
  • 8 Sarcoma Medical Oncology Department, The University of Texas M. D. Anderson Cancer Center, 77030 - Houston/US
  • 9 Sarcoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 77030 - Houston/US


Login to access the resources on OncologyPRO.

Abstract 1493MO


Recurrences are common after resection of DDLPS and UPS. We conducted a neoICB trial in resectable UPS and DDLPS pts and assessed peripheral immune biomarkers.


DDLPS (n=17) and UPS (n=10) patients (pts) were treated with neoICB; UPS pts received concurrent radiation. We performed RNA sequencing of peripheral blood mononuclear cells (PBMCs) and tumor specimens collected at baseline, on treatment and at surgery and single sample gene set enrichment analysis (ssGSEA) to quantify 30 immune cell types/signatures. The peripheral TCR repertoire (richness, clonality, density) was assessed by TCR-sequencing of DNA extracted from PBMCs. Correlation between peripheral and tumor immune scores were calculated by Spearman correlation test. Longitudinal comparisons between variables were done using ANOVA tests. Progression-free survival (PFS) was defined from time of neoICB start to progression on neoICB or relapse after surgery. Survival curves were compared using log-rank tests.


Median follow-up was 30 months from start of ICB treatment. Median PFS was 20 months (DDLPS: 18 months; UPS: Not Reached), with 15 progression events (12 DDLPS, 3 UPS). None of the peripheral ssGSEA scores correlated with their tumor counterparts at any time point. There was no significant change in any peripheral ssGSEA score nor TCR richness or clonality upon ICB treatment. Peripheral TCR density decreased with ICB treatment (p<0.001; DDLPS: p=0.0037; UPS: p=0.0027). Pts with higher peripheral TCR densities (above median) on treatment had improved PFS (p=0.049). Higher peripheral TCR richness (above median) at baseline showed a trend towards better PFS (p=0.1) and was also seen on treatment (p=0.08) but not at surgery (p=0.81).


In UPS and DDLPS patients undergoing neoICB, we were unable to identify a correlation between peripheral and tumor immune cells and signatures. However, peripheral TCR richness and density at baseline and during treatment may identify pts with better prognosis.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

The authors.




A. Reuben: Financial Interests, Personal, Advisory Board: Adaptive Biotechnologies. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.